San Diego Convention Center, site of the 2016 ASH Annual Meeting.

The 58th ASH Annual Meeting & Exposition took place December 3-6, 2016, in San Diego, California.

Artificial RBCs show promise in preclinical study

Print Friendly, PDF & Email


BALB-c_lab_mice_Credit_Aaron_Logan_230_v5.jpg
Lab mice
Photo by Aaron Logan

Researchers have developed artificial red blood cells (RBCs) that appear able to emulate functions of natural red blood cells (RBCs), at least in rodents. The artificial RBCs, known as ErythroMer, are designed to be freeze-dried, stored at ambient temperatures, and reconstituted with water when needed. If ErythroMer proves... [Read Article]

Print Friendly, PDF & Email

Combos prove no better than 7+3 for AML

Print Friendly, PDF & Email


Garcia-Manero_Guillermo_MD_Credit_MD_Anderson_Cancer_Center_220.jpg
Guillermo Garcia-Manero, MD
Photo courtesy of
MD Anderson Cancer Center

Neither a 2-drug combination nor a 3-drug combination is superior to 7+3 chemotherapy in younger patients with previously untreated acute myeloid leukemia (AML), according to a phase 3 trial. Treatment with idarubicin and high-dose cytarabine (IA), with or without vorinostat (V), was no... [Read Article]

Print Friendly, PDF & Email

HU trial to prevent stroke in SCA feasible in Nigeria

Print Friendly, PDF & Email


Galadanci_Najibah_MBBS_Todd Buchanan 2016.png
Najibah Galadanci, MBBS
© Todd Buchanan 2016

High rates of recruitment (90%), enrollment (92%), and adherence to study drug and follow-up visits have confirmed the feasibility of conducting a trial of hydroxyurea (HU) for stroke prevention in Nigeria (the SPIN trial), researchers say. The 235 children with sickle cell anemia... [Read Article]

Print Friendly, PDF & Email

Old drug, new tricks possible in MM

Print Friendly, PDF & Email


Driessen_Christoph_MD_PhD.png
Christoph Driessen, MD, PhD

An antiretroviral drug used to treat the human immunodeficiency virus (HIV) may find a role in the treatment of multiple myeloma (MM) patients who are proteasome inhibitor (PI)-refractory. According to investigators, nelfinavir may sensitize refractory patients so that PI-based treatments become an option for them. In a phase 2 study of... [Read Article]

Print Friendly, PDF & Email

MM patients with t(11;14) benefit from venetoclax

Print Friendly, PDF & Email


Kumar_Shaji_MD.jpg
Shaji Kumar, MD

Venetoclax, the oral BCL-2 inhibitor approved by the US Food and Drug Administration to treat chronic lymphocytic leukemia patients with 17p deletion, is also showing activity in multiple myeloma (MM) patients, particularly those with t(11;14) translocation. Final results of a phase 1 study showed venetoclax to be safe as monotherapy in relapsed... [Read Article]

Print Friendly, PDF & Email

KTE-C19 feasible in most young, high-risk ALL patients, study suggests

Print Friendly, PDF & Email


ped_ALL_pt_receiving_chemo_Bill_Branson_230.jpg
ALL patient
Photo by Bill Branson

Trial results suggest treatment with the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 is feasible for most young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). Nearly all ALL patients in this trial were able to receive their assigned dose of KTE-C19 after a preparative chemotherapy regimen. The... [Read Article]

Print Friendly, PDF & Email

G-CHOP no better than R-CHOP in previously untreated DLBCL

Print Friendly, PDF & Email


obinutuzumab-gazyva-240.png
Vial of obinutuzumab

Substituting obinutuzumab for rituximab in combination with CHOP chemotherapy does not improve outcomes in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to a study presented at the 2016 ASH Annual Meeting. In this phase 3 trial, known as GOYA, researchers compared obinutuzumab plus CHOP (G-CHOP) to rituximab plus CHOP... [Read Article]

Print Friendly, PDF & Email

Combined checkpoint blockade promising in HL

Print Friendly, PDF & Email


ASH2016-outside-Todd-Buchanan-230.jpg
2016 ASH Annual Meeting
© Todd Buchanan 2016

Immune checkpoint blockade with nivolumab plus ipilimumab has shown promise in treating hematologic malignancies, particularly classical Hodgkin lymphoma (HL), based on results of the combination cohort of the phase 1 CheckMate 039 study. Thirty-one heavily pretreated HL patients achieved an overall response rate (ORR) of 74%,... [Read Article]

Print Friendly, PDF & Email

Ruxolitinib may prevent CRS after CAR T-cell therapy

Print Friendly, PDF & Email


mouse_SCID_Credit_NCI_230.jpg
SCID mouse
Photo courtesy of NCI

A novel xenograft model of acute myeloid leukemia (AML) demonstrated that the JAK/STAT inhibitor ruxolitinib can prevent severe cytokine release syndrome (CRS) without impairing the anti-tumor effect of chimeric antigen receptor (CAR) T cells, according to research presented at the 2016 ASH Annual Meeting. Almost all patients responding to... [Read Article]

Print Friendly, PDF & Email

Trial supports early treatment of lower-risk ET

Print Friendly, PDF & Email


prescriptions_Credit_CDC_230.jpg
Prescription medications
Photo courtesy of CDC

Results from the ARETA trial suggest patients with essential thrombocythemia (ET) can benefit from early treatment even if they are not considered high-risk. In this phase 3 trial, non-high-risk patients were less likely to experience ET-related cardiovascular events or disease progression if they received extended-release anagrelide rather than... [Read Article]

Print Friendly, PDF & Email

MDS patients with mutated IDH2 benefit from enasidenib

Print Friendly, PDF & Email


stein-eytan-ASH14-230.jpg
Eytan Stein, MD
Photo courtesy of ASH

Daily treatment with enasidenib monotherapy in patients with mutated IDH2-positive myelodysplastic syndromes (MDS) induced responses in the majority of patients treated, according to a presentation at the 2016 ASH Annual Meeting. The study was a portion of a larger phase 1/2 trial of the agent in patients... [Read Article]

Print Friendly, PDF & Email

CAR met primary endpoint at interim analysis in DLBCL

Print Friendly, PDF & Email


The chimeric antigen receptor (CAR) T-cell therapy KTE-C19 has met its primary endpoint at the pre-specified interim analysis of the phase 2 ZUMA-1 trial in diffuse large B-cell lymphoma (DLBCL), according to data presented at the 2016 ASH Annual Meeting.DLBCL patients had an overall response rate (ORR) of 76% and a complete response (CR) rate of 47% (P<0.0001) after... [Read Article]
Print Friendly, PDF & Email

Study reveals CML patients likely to benefit from HSCT long-term

Print Friendly, PDF & Email


HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
HSCT preparation
Photo by Chad McNeeley

New research may help inform the management of patients with chronic myeloid leukemia (CML), according to a speaker at the 2016 ASH Annual Meeting. The study revealed a group of CML patients who appear most likely to benefit from allogeneic hematopoietic stem cell transplant (allo-HSCT) in the long... [Read Article]

Print Friendly, PDF & Email

Two mutations may help drive CBF-AML

Print Friendly, PDF & Email


ASH2016-posters-ER-230.jpg
Poster session at the
2016 ASH Annual Meeting

Researchers have found evidence to suggest that mutations in the CCND1 and CCND2 genes may contribute to the development of core-binding factor acute myeloid leukemia (CBF-AML). The team noted that CBF-AML is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. However, the fusion genes alone... [Read Article]

Print Friendly, PDF & Email